Skip to main content
Journal cover image

Recombinant hirudin for prevention of experimental postoperative intraocular fibrin.

Publication ,  Journal Article
Nasir, MA; Toth, CA; Mittra, RA
Published in: Am J Ophthalmol
May 1996

PURPOSE: To determine the efficacy of a specific antithrombin agent (recombinant desulphatohirudin variant 1 [Revasc, Ciba-Geigy, Ltd., Basel, Switzerland]) administered in the infusion fluid to prevent early postoperative fibrin formation in a rabbit lensectomy and vitrectomy model. METHODS: Standard fragmatome lensectomies and core vitrectomies were performed prospectively in a masked fashion on ten control eyes with lactated Ringer's infusion and on ten eyes treated with 10 microgram of recombinant hirudin/ml in the infusate. The amounts of fibrin and hemorrhage were graded in a masked fashion by using slit-lamp examination and indirect ophthalmoscopy on postoperative days 1 through 5 and on day 7. RESULTS: The difference in the mean grade of fibrin formed on the first postoperative day in the eyes treated with recombinant hirudin (mean, 0.9) in relation to the mean grade of fibrin in the control eyes (mean, 3.5) was statistically significant (P = .004). This difference was also significant on the second postoperative day (P = .01). None of the treated eyes developed intraoperative or postoperative hemorrhage. CONCLUSIONS: Recombinant desulphatohirudin variant 1 is an effective inhibitor of postoperative fibrin formation in a rabbit model and is not associated with an increased risk of intraoperative or postoperative bleeding at the tested dose. This drug may be a useful adjunct in vitreous surgery for both proliferative vitreoretinopathy and the complications of proliferative diabetic retinopathy.

Duke Scholars

Published In

Am J Ophthalmol

DOI

ISSN

0002-9394

Publication Date

May 1996

Volume

121

Issue

5

Start / End Page

554 / 560

Location

United States

Related Subject Headings

  • Vitrectomy
  • Thrombolytic Therapy
  • Recombinant Proteins
  • Rabbits
  • Prospective Studies
  • Postoperative Complications
  • Ophthalmology & Optometry
  • Lens, Crystalline
  • Hirudin Therapy
  • Fibrinolytic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nasir, M. A., Toth, C. A., & Mittra, R. A. (1996). Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. Am J Ophthalmol, 121(5), 554–560. https://doi.org/10.1016/s0002-9394(14)75430-3
Nasir, M. A., C. A. Toth, and R. A. Mittra. “Recombinant hirudin for prevention of experimental postoperative intraocular fibrin.Am J Ophthalmol 121, no. 5 (May 1996): 554–60. https://doi.org/10.1016/s0002-9394(14)75430-3.
Nasir MA, Toth CA, Mittra RA. Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. Am J Ophthalmol. 1996 May;121(5):554–60.
Nasir, M. A., et al. “Recombinant hirudin for prevention of experimental postoperative intraocular fibrin.Am J Ophthalmol, vol. 121, no. 5, May 1996, pp. 554–60. Pubmed, doi:10.1016/s0002-9394(14)75430-3.
Nasir MA, Toth CA, Mittra RA. Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. Am J Ophthalmol. 1996 May;121(5):554–560.
Journal cover image

Published In

Am J Ophthalmol

DOI

ISSN

0002-9394

Publication Date

May 1996

Volume

121

Issue

5

Start / End Page

554 / 560

Location

United States

Related Subject Headings

  • Vitrectomy
  • Thrombolytic Therapy
  • Recombinant Proteins
  • Rabbits
  • Prospective Studies
  • Postoperative Complications
  • Ophthalmology & Optometry
  • Lens, Crystalline
  • Hirudin Therapy
  • Fibrinolytic Agents